This overexpression of GPX4 in AML patients highlighted a potentially efficacious drug target in this cancer, and both studies found that inhibition of GPX4 with ML210 or RSL3 induced the death of AML cells in vitro [111,112]. The gene discussed is GPX4; the disease is acute myeloid leukemia.